09:50 AM EST - BioVaxys Technology Corp : Announces that interim results from its ongoing preclinical of BVX-1021, the Company's vaccine for SARS-CoV-1 which is being evaluated in a collaboration with The Ohio State University to develop a pan-sarbecovirus vaccine, show an excellent emerging tolerability profile with no observed side effects or noteworthy clinical observations. BVX-1021 is the subject of an ongoing research collaboration between Ohio State and BioVaxys that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses. BioVaxys Technology Corp
shares C.BIOV are trading unchanged at $0.16.
